NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase 1
Completed
- Conditions
- Adenocarcinoma of the ColonAdenocarcinoma of the GallbladderAdenocarcinoma of the PancreasAdenocarcinoma of the RectumAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the GallbladderDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMale Breast Cancer
- Interventions
- Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccineBiological: sargramostimBiological: recombinant fowlpox GM-CSF vaccine adjuvant
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00028496
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma
Phase 1
Completed
- Conditions
- AIDS-related Diffuse Large Cell LymphomaAIDS-related Diffuse Mixed Cell LymphomaAIDS-related Peripheral/Systemic LymphomaAIDS-related Small Noncleaved Cell Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00022555
- Locations
- 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States
EMD 121974 in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00022113
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00039390
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
BMS-247550 in Treating Patients With Stage IV Melanoma
Phase 2
Completed
- Conditions
- Recurrent MelanomaStage IV Melanoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT00036764
- Locations
- 🇺🇸
New York University Clinical Cancer Center, New York, New York, United States
Benzoylphenylurea in Treating Patients With Advanced Cancer
Phase 1
Terminated
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Other: pharmacological study
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00010205
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Bortezomib in Treating Patients With Recurrent Glioma
Phase 1
Terminated
- Conditions
- Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00006773
- Locations
- 🇺🇸
New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Phase 2
Completed
- Conditions
- Advanced Malignant MesotheliomaEpithelial MesotheliomaRecurrent Malignant MesotheliomaSarcomatous Mesothelioma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00039182
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)
Phase 2
Terminated
- Conditions
- Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- Biological: recombinant fowlpox-prostate specific antigen vaccineBiological: recombinant vaccinia prostate-specific antigen vaccineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT00005039
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Phase 1
Completed
- Conditions
- Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00002913
- Locations
- 🇺🇸
Gynecologic Oncology Group of Arizona, Phoenix, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath